Constâncio et al. created a plasma ctDNA assay that detected methylation levels of FOXA1, RARβ2, and RASSF, which identified prostate cancer with 64% sensitivity and 70% specificity from samples of 102 lung cancer, 121 prostate cancer, 100 colorectal patients, and 136 healthy subjects [40]. Here, FOXA1 is linked to prostate cancer.